---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-199931"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:16:01.394152+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older

## Summary
- FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.
- Management targets cash flow break-even in Q4 2024 and on a full-year basis in 2025.
- Proposed combination with Greenbrook TMS Inc. remains ongoing; stockholder approval pending.
- Company presenting at William Blair 44th Annual Growth Stock Conference on August 14, 2024.

## SEC filing metadata
- accession: 0001193125-24-199931
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312524199931/0001193125-24-199931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312524199931/d835019d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-199931
- JSON: https://secwatch.observer/filing/0001193125-24-199931.json
- Plain text: https://secwatch.observer/filing/0001193125-24-199931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.